Authors | Year | Outcome | Total sample size [n (narm 1, narm 2)] | No. lost to follow-up (%) | p-value | Journal impact factor | Fragility index | Overall ROB |
---|---|---|---|---|---|---|---|---|
Krupitsky et al. [22] | 2004 | Treatment retention | 52 (25, 27) | 0 (0)a | <0.05 | 3.77 | 1 | Low |
Fischer et al. [25] | 1999 | Treatment retention | 60 (31, 29) | 0 (0)a | 0.03 | 6.53 | 2 | Some concerns |
Petitijean et al. [17] | 2001 | Treatment retention | 58 (31, 27) | 0 (0)a | 0.002 | 4.50 | 4 | Low |
Krook et al. [23] | 2002 | Treatment retention | 106 (51, 55) | 7 (6.6)a | <0.001 | 6.53 | 6 | Low |
Sees et al. [18] | 2000 | Treatment retention | 179 (91, 88) | 0 (0)a | 0.01 | 56.27 | 7 | Some concerns |
Kakko et al. [19] | 2003 | Treatment retention | 40 (20, 20) | 0 (0)a | 0.0001 | 79.32 | 8 | Low |
Yancovitz et al. [26] | 1991 | Heroin use | 301 (94, 75) | 132 (43.9) | <0.001 | 9.30 | 11 | High |
Hartnoll et al. [24] | 1980 | Treatment retention | 96 (52, 44) | 8 (8.3)a | 0.001 | 8.48 | 12 | Low |
Hulse et al. [21] | 2009 | Maintaining therapeutic level of naltrexone in blood | 69 (34, 35) | 9 (13.0) | <0.001 | 8.48 | 15 | Low |
Oviedo-Joekes et al. [20] | 2009 | Treatment retention | 226 (111, 115) | 6 (2.7)a | <0.001 | 91.25 | 26 | Low |